Cardiac Glycosides from the Seeds of Thevetia peruviana

  • J Nat Prod. 2016 Jan 22;79(1):38-50. doi: 10.1021/acs.jnatprod.5b00611.
Dan-Mei Tian  1 ,  Huo-Yun Cheng  2 ,  Miao-Miao Jiang  3 ,  Wei-Zai Shen  2 ,  Jin-Shan Tang  4 ,  Xin-Sheng Yao  1
Affiliations
  • 1. College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University , Shenyang 110016, People's Republic of China.
  • 2. Department of Anatomy, Medical College, Jinan University , Guangzhou 510632, People's Republic of China.
  • 3. Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine , 88 Yuquan Road, Nankai District, Tianjin 300193, People's Republic of China.
  • 4. Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University , Guangzhou 510632, People's Republic of China.
PMID: 26714048 DOI: 10.1021/acs.jnatprod.5b00611
Abstract

Investigation of the seeds of Thevetia peruviana resulted in the isolation of 15 new (2-16) and 18 known (1 and 17-33) cardiac glycosides. Eight 19-nor-cardenolides (1-8), including two rare 19-nor-10-hydroperoxycardenolides, were obtained from T. peruviana for the first time. All the structures were characterized by NMR spectroscopy and chemical derivatization. The inhibitory effects of cardiac glycosides 1-33 against three Cancer cell lines (human lung Cancer cells, P15; human gastric Cancer cells, MGC-803; and human pancreatic Cancer cells, SW1990) and one normal hepatocyte cell line, LO2, were evaluated, and a preliminary structure-activity relationship is discussed. In addition, cardiac glycosides 1, 22, 26, and 28 were evaluated for their apoptosis-inducing activities in MGC-803 cells, showing IC50 values in the range 0.02-0.53 μM.

Products